A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors
Memorial Sloan Kettering Cancer Center
60 participants
Apr 7, 2026
INTERVENTIONAL
Conditions
Summary
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BMS-986504 PO daily
Ipilimumab (1mg/kg Q6wk)
Nivolumab (360mg flat dose Q3wk)
are continued until disease progression or intolerance
are continued until disease progression or intolerance
are continued until disease progression or intolerance
Gemcitabine are given for a maximum of 6 cycles
Platinum are given for a maximum of 6 cycles
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07532902